Sterile benzylpenicillin sodium is filled as a dry crystalline mass into cleaned and depyrogenated USP Type I borosilicate glass vials on an aseptic powder filling line equipped with a restricted access barrier system or isolator. The terminal product is not subjected to terminal sterilization because moist heat cycles above 30°C accelerate beta-lactam hydrolysis and reduce potency below pharmacopoeial assay limits; therefore the line operates under EU GMP Annex 1:2022, ISO 14644-1:2015 Class 5, and USP <71> sterility assurance. The fill weight per vial is 0.600 g for 1 million IU and 3.0 g for 5 million IU, with a fill tolerance of ±3% w/w; addition of sodium citrate as a buffering agent ranges from 0.1% w/w to 0.5% w/w when a pH buffer is required, though many commercial vials contain no added excipients. The reconstitution solution after adding Water for Injection or 0.9% sodium chloride injection must remain in the pH range of 5.0 to 7.0. Downstream production starts with aseptic crystallization and vacuum drying to a moisture content of not more than 1.0% w/w; the powder is passed through a 500 µm stainless steel sieve and loaded into the filling hopper under inert conditions. Production-scale equipment includes the Syntegon FP 4060 or Optima PF series filling machines; a commonly encountered failure mode is electrostatic adhesion of the low-bulk-density powder to the dosing disc, causing fill weight drift across vials, which is controlled by maintaining relative humidity below 30% RH and grounding all metal contact surfaces. The vials are sealed with Flurotec-coated bromobutyl stoppers and aluminum flip-off seals, then inspected for visible particles per USP <790>. Terminal product types include 1 million IU, 5 million IU, and 10 million IU vials for intravenous infusion or intramuscular injection. The intramuscular route may use lidocaine hydrochloride 1% as a diluent only when specified in the product license; Water for Injection is the standard diluent. Published data for specific vial line speeds and filling bowl configurations are limited, but the above parameters are derived from commonly observed production practice. Benzylpenicillin sodium solutions should not be mixed in the same intravenous line with aminoglycosides because mutual inactivation can occur; this incompatibility is well documented and restricts bedside admixture practice.

When Lyophilization Replaces Crystalline Powder Filling in Intravenous Dose Units

When a lyophilized presentation is selected instead of direct dry powder filling, the sterile API is first dissolved in Water for Injection at 200–250 mg/mL under aseptic conditions. The resulting solution is passed through a 0.22 µm polyethersulfone membrane filter preceded by a 0.45 µm polypropylene prefilter, with the filtration train validated for microbial retention per ICH Q2(R2) and membrane integrity challenge. The filtered solution is filled into partially stoppered vials and loaded into a freeze dryer. A typical cycle includes freezing at -40°C for 2 hours, primary drying at -20°C and 0.2 mbar for 12–16 hours, and secondary drying at +25°C until residual moisture is not more than 2.0% w/w. Benzylpenicillin sodium forms a dense crystalline cake without added bulking agent; when a more rigid cake is required for automated inspection, mannitol is added at 5.0% w/v of the filling solution, corresponding to 0.25 g per 5 mL fill volume. The API strength remains 0.600 g or 3.0 g per vial. Terminal product types include lyophilized powder vials for IV injection, especially for markets where a faster reconstitution time is specified. Compliance requirements include USP <1> Injections, USP <71>, USP <85> with endotoxin limit based on dose, USP <788> particulate matter after reconstitution, and EU GMP Annex 1:2022 for lyophilizer loading and unloading. Production-scale lyophilizers such as the GEA Lyovac series with shelf temperature control of ±1°C are used. A known processing conflict is the potential for glass vial breakage during freeze-drying if the fill volume exceeds 40% of the nominal vial capacity; the fill volume is therefore limited to 5 mL in 10 mL vials for 0.600 g product and 15 mL in 30 mL vials for 3.0 g product. Residual moisture testing by Karl Fischer titration per USP <921> is performed after stopper sealing under partial vacuum or nitrogen. Published data for benzylpenicillin sodium lyophilized cake morphology are sparse; formulators rely on cycle development and real-time mass spectrometry for moisture end point.

In oral tablet development using this sterile API, three constraints dominate scale-up: the beta-lactam ring degrades at gastric pH, the crystalline powder exhibits poor flow, and direct compression without prior granulation produces unacceptable weight variation on high-speed rotary presses. The acid-labile solid is therefore processed by dry granulation, not aqueous wet granulation, and the compressed cores are protected with a methacrylic acid–ethyl acrylate copolymer enteric coating. Feasibility compaction studies establish a drug loading band of 25–45% w/w in the core, with microcrystalline cellulose PH102 at 20–35% w/w as a dry binder, crospovidone at 2–5% w/w as a superdisintegrant, and magnesium stearate at 0.5–1.0% w/w as a lubricant. For a 250 mg benzylpenicillin tablet, the total core weight is 600 mg, and the mixture is first blended in a bin blender at 10 rpm for 15 minutes. The blend is compacted on a Gerteis Mini-Pactor or Alexanderwerk WP 120 using a roll force of 10–18 kN/cm, a gap width of 2.0 mm, and a roll speed of 2–5 rpm; the resulting ribbons are milled through a Quadro Comil 197S equipped with a 0.8 mm screen at 1,500 rpm. The granules are compressed into tablets at a hardness of 6–9 kP and a friability of not more than 1.0% w/w. The enteric coating is applied as an aqueous dispersion of Eudragit L 30 D-55 in a Glatt GC 750 pan coater; triethyl citrate is used at 10% of polymer solids, talc at 30% of polymer solids, and the coating suspension is diluted to 20% solids with purified water. The target coating weight gain is 10–15% w/w to ensure that acid uptake in 0.1 M HCl does not exceed 10% in 2 hours. Dissolution is tested in USP <711> apparatus II at 50 rpm, first in 0.1 M HCl for 2 hours and then in pH 6.8 phosphate buffer; the buffer-stage acceptance criterion is NLT 80% released in 45 minutes. Terminal product types are 250 mg and 500 mg enteric-coated tablets for oral administration. Compliance is anchored to USP <701>, USP <711>, USP <905>, USP <1217> for breaking force, ICH Q3C for residual coating solvents, ICH Q3D for elemental impurities, and FDA 21 CFR 211 for current good manufacturing practice. In production scale, the moisture sensitivity of the granulation requires inlet air dew point below -10°C during coating and a relative humidity in the compression suite below 45% RH; pre-drying of microcrystalline cellulose at 60°C for 2 hours before blending is required if stored above 60% RH. The commercial availability of oral benzylpenicillin sodium tablets is limited, and published data for exact commercial formulations remain sparse.

What Are the Feasibility Limits for Hard Gelatin Capsule Manufacturing with Acid-Labile Benzylpenicillin Sodium?

For hard capsule filling, the raw sterile API cannot be directly dosed into hard gelatin or HPMC capsules because its low bulk density and electrostatic charge cause erratic auger filling and weight variability exceeding USP <905> limits. The powder is therefore converted into enteric-coated multiparticulates, and the capsules are filled with coated pellets rather than powder. In this process, the API is blended with microcrystalline cellulose spheres or formulated into a pellet core by extrusion-spheronization. The pellet core composition is typically 20–40% w/w benzylpenicillin sodium, 40–50% w/w microcrystalline cellulose, 10–20% w/w lactose monohydrate, and 3–5% w/w crospovidone; purified water is used as the granulation fluid during extrusion and is removed in a fluid bed. Extrusion is performed through a 0.8 mm screen in a Caleva Multi Lab extruder at 30–50 rpm, followed by spheronization at 800–1,200 rpm in a Caleva spheronizer with a 5 mm plate. The pellets are dried at 45°C in a fluidized bed to residual moisture below 3.0% w/w, then coated with Eudragit L 30 D-55 in a Glatt GPCG 1.1 fluid bed; the coating weight gain is 12–18% w/w and the product temperature during coating is maintained at 25–30°C to avoid polymer phase separation and agglomeration. The coated pellets are filled into size 1 or size 0 hard HPMC capsules using a Bosch GKF 720 intermittent capsule filler at a fill weight of 450 mg for a 250 mg dose, with 100% weight sorting and metal detection. Terminal product types include 400,000 IU and 800,000 IU hard capsules for oral use, specifically designed for patients who cannot tolerate injectable therapy and where penicillin V or another oral beta-lactam is not available. Compliance includes USP <701> for capsule disintegration with a delay time of not more than 5 minutes in pH 6.8 buffer, USP <711> for two-stage dissolution, USP <921> for moisture, ICH Q3D for elemental impurities, and FDA 21 CFR 211 for capsules containing beta-lactam actives. The most frequent production-scale failure mode is pellet agglomeration in the Wurster coater when the spray rate exceeds 8 g/min/kg; lowering the spray rate and increasing the airflow prevents the bed from collapsing. In the capsule filler, static charge on coated pellets is controlled with an ionizing air bar and grounding. Published data for this specific oral capsule configuration is limited.

In sachet-based oral granule production, benzylpenicillin sodium is processed into coated multiparticulate granules rather than a reconstitutable dry syrup, because reconstitution in an aqueous vehicle before administration would release the acid-labile beta-lactam and reduce gastric survival. The granules are formed by low-shear granulation with a povidone K30 binder solution, but the water content is kept low; the granulation is followed by extrusion-spheronization or rotor granulation in a fluidized bed. A representative granule core contains 15–30% w/w benzylpenicillin sodium, 50–60% w/w microcrystalline cellulose spheres, 5–10% w/w lactose monohydrate, and 1–3% w/w crospovidone. The binder solution is prepared with purified water at 5% w/w povidone K30; the wet mass is passed through a 0.6 mm screen and spheronized at 1,000–1,500 rpm for 3–5 minutes. The granules are dried at 40–50°C in a Glatt GPCG 1.1 fluid bed to a moisture content below 2.0% w/w. The dried granules are then coated with Eudragit L 30 D-55 to a weight gain of 10–15% w/w, with triethyl citrate and talc as plasticizer and anti-tackifier. The coated granules are filled into aluminum foil sachets at 125 mg, 250 mg, or 500 mg dose using a sachet powder filler under nitrogen blanket; the residual oxygen in the sachet headspace is maintained below 1.0% v/v to prevent oxidative degradation. Terminal product types are single-dose sachets of enteric-coated oral granules for direct administration with soft food or for swallowing with water, intended for niche oral use where parenteral benzylpenicillin is not feasible. Compliance includes USP <711> dissolution using the two-stage acid-buffer method, USP <905> uniformity of dosage units by mass variation, ICH Q3D for elemental impurities, and ICH Q3C for residual solvents. The production-scale issue is granule friability during spheronization: if the spheronizer speed exceeds 1,500 rpm, fines generate electrostatic clumping and cause sachet fill weight drift; the process is therefore operated at the lower end of the speed range and the granules are screened through a 1.0 mm sieve before coating. Published data for commercial oral benzylpenicillin sodium granule products are limited; the above parameters reflect a formulation development window based on enteric-coating principles rather than marketed product data.

Extemporaneous Hospital Pharmacy Compounding Stabilized by Cold-Chain Verification

In hospital pharmacy practice, sterile benzylpenicillin sodium vials are reconstituted and diluted into ready-to-infuse syringes or infusion bags using USP <797> for sterile compounding. The process is not manufacturing but represents a real downstream distribution and administration pathway for the sterile API. The reconstitution is performed by adding 9.6 mL of Water for Injection to a 0.600 g vial to produce 10 mL at 60 mg/mL; this concentrate is then further diluted with 0.9% sodium chloride injection or 5% dextrose injection to a final concentration of 50–100 mg/mL for intermittent intravenous infusion. Terminal product types include ready-to-infuse syringes, elastomeric infusors, and polypropylene infusion bags prepared under ISO Class 5 conditions. In-use stability limits recognize that benzylpenicillin sodium degrades in aqueous solution; diluted preparations are stored at 2–8°C and must be administered within 24 hours unless a longer period is validated by high-performance liquid chromatography. The equipment includes B. Braun or ICU Medical closed system transfer devices and refrigerated storage verified with continuous temperature monitoring. A known operational failure mode is underestimation of beyond-use dating when admixtures are left at room temperature in automated dispensing cabinets; this is addressed by labeling with an immediate-use time of 1 hour at controlled room temperature and a refrigerated time of 24 hours. Published stability data for high-concentration benzylpenicillin infusions in specific elastomeric devices are limited; hospital pharmacy departments often perform local bracketing studies to confirm the assigned beyond-use date.